MarketPulse
D

$DFTX

3 articles found
3 positive
0 negative
0 neutral
Investing.comInvesting.com··Nathan Reiff

Trump's Psychedelic Order Ignites Biotech Rally, But Valuations Raise Caution

Trump's April 2026 executive order grants FDA priority vouchers to psychedelic biotech firms, triggering stock surges for Compass Pathways, AtaiBeckley, and Definium Therapeutics amid speculative valuations.
DFTXCMPSPSILbiotechclinical trials
The Motley FoolThe Motley Fool··Matthew Benjamin

Trump's Psychedelic Fast-Track Order Opens New Frontier for FDA Approvals

Trump executive order accelerates psychedelic drug approvals from 6-10 months to 1-2 months, allocates $50M for research, benefiting biotech companies.
DFTXCMPStreatment-resistant depressionmental health
BenzingaBenzinga··Prnewswire

Psychedelic Drug Developers Entering Final Testing Phase for Mental Health Treatments

Five biotech firms advance psychedelic therapies to Phase 3 trials for depression and anxiety, with multiple readouts expected in 2026, marking progress toward regulatory approval.
ATAIDFTXGHRSLBRXpsychedelic biotechnologyPhase 3 trials